MedTrace Logo

Efficacy Parecoxib and Ketorolac as Preemptive Analgesia in Spine Fusion

NCT01859585 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2013-05-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of Parecoxib and Ketorolac as a preemptive analgesia in patients undergoing lumbar spinal fusion.

Conditions

  • Postoperative Pain

Interventions

DRUG

Parecoxib

Parecoxib 40 mg intravenous

DRUG

Ketorolac

Ketorolac 30 mg intravenous

Sponsors & Collaborators

  • Prince of Songkla University

    lead OTHER

Principal Investigators

  • Koopong Siribumrungwong, MD · Orthopedic Department, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2013-01-31
Completion
2013-03-31

Countries

  • Thailand

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01859585 on ClinicalTrials.gov